Eptinezumab Offers Lasting Relief for Resistant Migraine Sufferers

Research Summary

In a study published in the European Journal of Neurology, eptinezumab showed significant long-term benefits for migraine sufferers who had not found relief from 2-4 previous preventive treatments. The DELIVER trial, which included a 24-week randomized, double-blind, placebo-controlled phase followed by a 48-week extension, revealed that participants experiencing at least a 50% reduction in migraines during the initial 12 weeks maintained this improvement over 72 weeks. Specifically, 61% of those on 100 mg and 74% on 300 mg sustained their response. Participants also noted reduced migraine severity and improved daily functioning, suggesting promising long-term outcomes for eptinezumab.

Study Details

📄 Title: Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed.

👥 Research Team: Ailani J et al.

📚 Published In: Eur J Neurol

📅 Publication Date: 2026 Mar

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.